ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study

Key Takeaways Absci Corporation began dosing in its phase I/IIa study of ABS-201 for androgenetic alopecia.The HEADLINE study will assess safety, tolerability, PK, PD and early efficacy measures in healthy volunteers.Positive MAD results could advance ABS-201 to accelerated development as a potential new AGA therapy.Shares of Absci Corporation (ABSI) jumped 13.4% on Thursday after the company initiated dosing in an early-to-mid-stage study evaluating its investigational candidate, ABS-201, for androgenetic ...